Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies

  • STATUS
    Recruiting
  • End date
    Aug 1, 2023
  • participants needed
    81
  • sponsor
    Regeneron Pharmaceuticals
Updated on 7 May 2020
ipilimumab

Summary

The primary objective of the study is to assess the safety, tolerability, and Pharmacokinetics (PK) of REGN2810 in Japanese patients with advanced malignancies. The secondary objective of the study is to assess the immunogenicity of REGN2810.

Details
Treatment Ipilimumab, REGN2810, Platinum-doublet chemotherapy
Clinical Study IdentifierNCT03233139
SponsorRegeneron Pharmaceuticals
Last Modified on7 May 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 20 yrs?
Gender: Male or Female
Do you have Advanced Malignancies?
Disease types under study
Part 1: Histologically or cytologically confirmed diagnosis of malignancy with no alternative standard-of-care therapeutic option
Part 2: Patients with histologically or cytologically documented squamous or non-squamous NSCLC with stage IIIB or stage IV disease who received no prior systemic treatment for recurrent or metastatic NSCLC
Patients in Part 2 NSCLC cohorts must have available archival or newly obtained formalin-fixed tumor tissue from a metastatic/recurrent site, which has not previously been irradiated
ECOG (Eastern Cooperative Oncology Group) PS (Performance status) 1 (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature [eg, light house work or office work]). Note: Patients with ECOG PS >1 are ineligible
Patients must have been born in Japan, and their biological parents and grandparents must all have been of Japanese origin
Willing and able to comply with clinic visits and study-related procedures

Exclusion Criteria

Ongoing or recent (within 5 years) evidence of significant autoimmune disease that requires treatment with systemic immunosuppressive treatments, which may suggest risk for Immune-related adverse event (irAE)s. The following are not exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires only hormone replacement or psoriasis that does not require systemic treatment
Untreated brain metastasis (es) that may be considered active. Patients with previously treated brain metastases may participate provided they are stable, there is no evidence of new or enlarging brain metastases, and the patient does not require any systemic corticosteroids for management of brain metastases within 4 weeks prior to the first dose of REGN2810
Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of REGN2810
Any positive test (ribonucleic acid (RNA) or Deoxyribonucleic acid (DNA) by polymerase chain reaction) for hepatitis B, hepatitis C, or human immunodeficiency virus indicating uncontrolled active or chronic infection
History of pneumonitis or interstitial lung disease
Surgery within 1 month of first dose and radiation therapy within 2 weeks of first dose
Completed palliative radiation therapy within the prior 2 weeks or has not recovered from any medically significant radiation-related Adverse Event (AE)
Patients that have never smoked, defined as smoking 100 cigarettes in a lifetime (Part 2)
Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or ROS1 fusions (Part 2)
Note: Other protocol defined inclusion/exclusion criteria apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in .
Loading...

No made yet